Current Report Filing (8-k)
September 15 2020 - 9:02AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): September 14, 2020
RESHAPE
LIFESCIENCES INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
1-33818
|
|
48-1293684
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
1001 Calle Amanecer
San Clemente, CA
|
|
92673
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(949)
429-6680
(Registrant’s telephone number, including
area code)
Not applicable
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common stock, $0.001 par value per share
|
|
RSLS
|
|
OTCQB Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
|
Item 1.01
|
Entry into a Material Definitive Agreement.
|
As previously disclosed, on March 25, 2020, ReShape Lifesciences
Inc. (the “Company”) entered into a Credit Agreement (as amended from time to time, the “Credit Agreement”)
with Armistice Capital Master Fund Ltd. (the “Lender”) pursuant to which the Company borrowed the initial principal
amount of $2.5 million and an additional $1.0 million pursuant to delayed draw term loans. A copy of the Credit Agreement was filed
as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 31,
2020.
On September 14, 2020, the Company and the Lender entered
into an amendment to the Credit Agreement (the “Amendment”) that increased the amount available under delayed draw
term loans by $2 million. The Company borrowed $1 million of the available amount immediately and the remaining $1 million will
be available in increments of least $500,000 with at least 30 days between borrowings. Pursuant the Amendment, the maturity date
of the loans outstanding under the Credit Agreement, including those under the Amendment, was extended from September 24,
2020 to March 31, 2021. The loans bear interest at a rate per annum equal to the LIBOR rate plus 2.5%.
As an inducement to the Lender to enter into the Amendment and
make the additional loans contemplated thereby, the Company issued to the Lender a warrant dated September 14, 2020 (the “Warrant”)
to purchase an aggregate of 1,200,000 shares of the Company’s common stock, par value $0.001 per share (the “Common
Stock”), with an exercise price per share of Common Stock equal to $3.25, the closing market price of the Common Stock on
the date of the Warrant. The Warrant was issued in reliance on the exemption from registration contained in Section 4(a)(2) of
the Securities Act of 1933, as amended, and/or Rule 506 of Regulation D promulgated thereunder as transactions
by an issuer not involving any public offering.
The foregoing description of the Credit Agreement, Amendment
and Warrant are not complete and are qualified in their entirety by references to the full text of the form of Credit Agreement,
Amendment and Warrant. The Amendment and Warrant are filed hereto as Exhibits 10.1 and 10.2, respectively, to this report and are
incorporated by reference herein.
|
Item 2.03
|
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
|
The information disclosed in Item 1.01 of this Current Report
on Form 8-K is incorporated by reference into this Item 2.03.
|
Item 3.02
|
Unregistered Sales of Equity Securities.
|
The information disclosed in Item 1.01 of this Current Report
on Form 8-K is incorporated by reference into this Item 3.02.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
RESHAPE LIFESCIENCES INC.
|
|
|
|
|
|
|
|
|
By:
|
/s/ Barton P. Bandy
|
|
|
|
Barton P. Bandy
|
|
|
|
President and Chief Executive Officer
|
Dated: September 15, 2020